These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 8912368)
21. Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy. Blaickner M; Baum RP PET Clin; 2014 Jan; 9(1):99-112. PubMed ID: 25029939 [TBL] [Abstract][Full Text] [Related]
22. Dosimetry in Peptide radionuclide receptor therapy: a review. Cremonesi M; Ferrari M; Bodei L; Tosi G; Paganelli G J Nucl Med; 2006 Sep; 47(9):1467-75. PubMed ID: 16954555 [TBL] [Abstract][Full Text] [Related]
23. From the magic bullet to an effective therapy: the peptide experience. Mansi L Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1393-8. PubMed ID: 15351914 [No Abstract] [Full Text] [Related]
25. Single photon emission computed tomography and positron emission tomography in cancer imaging. Coleman RE Cancer; 1991 Feb; 67(4 Suppl):1261-70. PubMed ID: 1991287 [TBL] [Abstract][Full Text] [Related]
26. Patient-specific dosimetry in radionuclide therapy. Lyra M; Lagopati N; Charalambatou P; Vamvakas I Radiat Prot Dosimetry; 2011 Sep; 147(1-2):258-63. PubMed ID: 21831867 [TBL] [Abstract][Full Text] [Related]
27. Proposition: positron imaging with SPECT and dual-head scintillation cameras obviates the need for PET in oncologic imaging. Madsen MT; Harkness BA Med Phys; 1998 Nov; 25(11):2116-8. PubMed ID: 9829235 [No Abstract] [Full Text] [Related]
30. Radionuclide purity and radiation dosimetry of 124I used in positron tomography of the thyroid. Akbari RB; Ott RJ; Trott NG; Sharma HL; Smith AG Phys Med Biol; 1986 Jul; 31(7):789-91. PubMed ID: 3749264 [No Abstract] [Full Text] [Related]
31. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Leichner PK; Koral KF; Jaszczak RJ; Green AJ; Chen GT; Roeske JC Med Phys; 1993; 20(2 Pt 2):569-77. PubMed ID: 8492765 [TBL] [Abstract][Full Text] [Related]
32. Physical aspects of scintigraphy-based dosimetry for nuclear medicine therapy. Geworski L; Schaefer A; Knoop BO; Pinkert J; Plotkin M; Kirsch CM Nuklearmedizin; 2010; 49(3):85-95. PubMed ID: 20505893 [TBL] [Abstract][Full Text] [Related]
33. [Present and future prospects of external radiation cancer treatment]. Valuckas KP; Aleknavicius E; Grybauskas M Medicina (Kaunas); 2004; 40(12):1133-42. PubMed ID: 15630338 [TBL] [Abstract][Full Text] [Related]
34. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan. D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680 [TBL] [Abstract][Full Text] [Related]
35. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Bodey RK; Flux GD; Evans PM Cancer Biother Radiopharm; 2003 Feb; 18(1):89-97. PubMed ID: 12667312 [TBL] [Abstract][Full Text] [Related]
37. The importance of the accuracy of image registration of SPECT images for 3D targeted radionuclide therapy dosimetry. Papavasileiou P; Divoli A; Hatziioannou K; Flux GD Phys Med Biol; 2007 Dec; 52(24):N539-48. PubMed ID: 18065833 [TBL] [Abstract][Full Text] [Related]